After completing my fellowship in Medical Oncology and Hematology at the National Cancer Institute, National Institutes of Health in 2013, I pursued further drug development training in the Advanced Developmental Therapeutics Training Program (ADTTP) of the Division of Cancer Treatment and Diagnosis, National Cancer Institute. My training in this program exposed me to the various aspects of protocol development, the principles of biomarker development and incorporation of biomarkers that demonstrate proof-of-mechanism and target engagement in clinical trials. I interacted closely with the translational laboratories and investigators at the Cancer Therapy and Evaluation Program, NCI, to translate laboratory data into the clinic and to incorporate correlative studies in my clinical protocols. I was the lead associate investigator for a Phase 1 study of the first-in-class inhibitor of the WEE1 kinase, AZD1775 which was selected for oral presentation at the 2014 Annual Meeting of ASCO and for which I received a Merit Award. The results of this study have since been published in the Journal of Clinical Oncology. As part of this study, I also collaborated extensively with the Laboratory for Tumor Immunology and Biology, and coordinated the collection of patient blood samples for evaluation of markers of immune-mediated tumor lysis.
As part of my current appointment in the Early Drug Development Center (EDDC), Dana-Farber Cancer Institute, I am currently a co-investigator on several studies and am the Principal Investigator for an Investigator-initiated study of prexasertib, CHK1 inhibitor, in combination with olaparib, PARP inhibitor.